SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital
About this trial
This study will explore the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing cardiac ischemia and cardiopulmonary edema in patients with acute decompensated heart failure during weaning from ventilators.
Eligibility criteria
Qualifiers
Patients aged ≥20 years
Currently hospitalized for the primary diagnosis of acute HF (de novo or decompensated chronic HF) in HFrEF patients (LVEF≤40%)
Patients were intubated for at least 24 hour with ventilator settings allowing to initiate the weaning process [SpO2 > 90% or PaO2/FiO2 ≥ 150 mmHg with a fraction of inspired oxygen (FiO2) ≤ 40% and a positive end-expiratory pressure (PEEP) ≤ 8 cmH2O].
Disqualifiers
Decision to withdraw life support
Cardiogenic shock
Hospitalization for HF (HHF) triggered by acute myocardial infarction (AMI) or pulmonary embolism
Planned or previous (within 30 days) cardiovascular revascularization or major cardiac surgery/intervention/device implantation
Trial design
Treatments tested in this trial
- SGLT2 inhibitor
Treatment groups
450 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov